Sugi Predict

Sugi Predict / Targets / CNR2

CNR2

Cannabinoid receptor 2 · P34972 · CNR2 on Sugi Atlas →

578,056 patent compounds predicted against CNR2, 253,787 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL39060 SCHEMBL39060 0.54 20/20
SCHEMBL69123 SCHEMBL69123 0.58 17/20
SCHEMBL51668 SCHEMBL51668 0.55 17/20
Dronabinol Dronabinol (SCHEMBL4609) 1.00 16/20
SCHEMBL72985 SCHEMBL72985 0.51 15/20
Lenabasum Lenabasum (SCHEMBL26441) 1.00 14/20
Nabilone Nabilone (SCHEMBL33339) 1.00 14/20
SCHEMBL18671 SCHEMBL18671 0.56 14/20
SCHEMBL47150 SCHEMBL47150 0.55 13/20
SCHEMBL71158 SCHEMBL71158 0.47 13/20
SCHEMBL63859 SCHEMBL63859 0.50 12/20
SCHEMBL16278 SCHEMBL16278 0.49 12/20
SCHEMBL59244 SCHEMBL59244 0.36 11/20
SCHEMBL59464 SCHEMBL59464 0.36 11/20
SCHEMBL43704 SCHEMBL43704 0.55 10/20
SCHEMBL58612 SCHEMBL58612 0.37 10/20
SCHEMBL58400 SCHEMBL58400 0.35 10/20
SCHEMBL67493 SCHEMBL67493 0.44 9/20
SCHEMBL51810 SCHEMBL51810 0.53 8/20
SCHEMBL9147 SCHEMBL9147 0.51 8/20

Clinical trials — most relevant to CNR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment Strategies in CHS PHASE4COMPLETED
Investigating the Effects of Nabilone on Endocannabinoid Metabolism PHASE4COMPLETED
Sativex for Treatment of Chemotherapy Induced Neuropathic Pain PHASE3COMPLETED
Effect of Hemp-CBD on Patients With CIPN PHASE2UNKNOWN
Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD) PHASE1/PHASE2RECRUITING
Topical Cannabidiol for Treating Carpal Tunnel Syndrome PHASE2NOT_YET_RECRUITING
A Trial Assessing the Effect of Nabilone on Pain and Quality of Life in Patients With Fibromyalgia PHASE2COMPLETED
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder PHASE2RECRUITING
Treatment for Cannabis Withdrawal and Dependence PHASE2COMPLETED
The Effects of CBD Isolate on Menstrual-Related Symptoms PHASE2COMPLETED
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes PHASE1COMPLETED
A Study Investigating the Bioavailability of CBD and THC in an Emulsion Product in a Healthy Population PHASE1COMPLETED
A Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults PHASE1COMPLETED
Antagonist-Elicited Cannabis Withdrawal PHASE1COMPLETED
The Role of Endocannabinoids in Insulin Production and Action PHASE1COMPLETED
In Vivo Study of THC-induced Immune-genome Changes at Single Cell Solution in HIV-infected Humans PHASE1COMPLETED
Topical Cannabidiol Cream and Post-exercise Recovery EARLY_PHASE1WITHDRAWN
Brain Imaging of Cannabinoid Receptors EARLY_PHASE1COMPLETED
Effect of OMM on Anandamide Levels in Saliva nanCOMPLETED
Imaging Cannabinoid CB1 Receptors in Alcohol Dependence nanCOMPLETED
Effects of Probiotics on Gut Microbiota, Endocannabinoid and Immune Activation and Symptoms of Fatigue in Dancers nanCOMPLETED
Acute and Chronic Toxicity of Some Synthetic Cannabinoids in Assiut Psychiatric Hospitals nanUNKNOWN
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery nanCOMPLETED
Psychological and Biological Markers of Refractory Migraine nanUNKNOWN
Pharmacogenetic Variation: Factors That May Affect the Efficacy and Safety of Medical Marijuana nanCOMPLETED
Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region nanCOMPLETED
Cytokine Production of Colonic Tissue From IBD Patients nanUNKNOWN
Concentration of Receptors With Affinity for Cannabidiol and Cannabinol and the Effect on Chronic Orofacial Pain of Muscle Origin nanENROLLING_BY_INVITATION
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Cannabinoids for Osteoarthritis Pain Effectiveness Trial nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CNR2 binder may also engage these)

ProteinNameSimilarity
Q9QZN9 — 0.998 Q9QZN9 →
P47936 — 0.993 P47936 →
P47752 — 0.983 P47752 →
P56448 — 0.983 P56448 →
GPR119 Glucose-dependent insulinotropic receptor 0.981 landscape →
Q6A155 — 0.981 Q6A155 →
P52592 — 0.980 P52592 →
P11617 — 0.979 P11617 →
S1PR2 Sphingosine 1-phosphate receptor 2 0.979 landscape →
O19037 — 0.978 O19037 →
Q864K7 — 0.978 Q864K7 →
Q9Z0L1 — 0.976 Q9Z0L1 →
Q7TQP3 — 0.976 Q7TQP3 →
Q6TLI7 — 0.976 Q6TLI7 →
Q864I2 — 0.975 Q864I2 →
Q864K5 — 0.975 Q864K5 →
Q91178 — 0.975 Q91178 →
Q0Q460 — 0.973 Q0Q460 →
P56447 — 0.973 P56447 →
P56446 — 0.973 P56446 →
Q864K4 — 0.973 Q864K4 →
Q864K9 — 0.973 Q864K9 →
Q864K0 — 0.973 Q864K0 →
Q864J6 — 0.972 Q864J6 →
Q864G9 — 0.972 Q864G9 →
Q864G2 — 0.972 Q864G2 →
O77616 — 0.972 O77616 →
Q864J0 — 0.972 Q864J0 →
Q864F5 — 0.971 Q864F5 →
P56445 — 0.971 P56445 →